Incyte(INCY.US)

Last Updated 19:00:00 ET
longbridge loading

Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

MarketWatch Automated·
US
INCY
+1.55%
US
BBH
+0.96%
US
PBE
+1.60%
MarketWatch Automated·
US
INCY
+1.55%
US
BBH
+0.96%
US
PBE
+1.60%

<![CDATA[Pharmaceutical Executive Daily: Eli Lilly Acquires Engage Bio]]>

Pharmexec·
US
BMY
+0.39%
US
INCY
+1.55%
US
LLY
-0.25%
Pharmexec·
US
BMY
+0.39%
US
INCY
+1.55%
US
LLY
-0.25%

Incyte Stock: Analyst Estimates & Ratings

Barchart Option·
US
INCY
+1.55%
US
LABD
-11.45%
US
IHE
+0.84%
Barchart Option·
US
INCY
+1.55%
US
LABD
-11.45%
US
IHE
+0.84%

Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build

Market Beat·
US
INCY
+1.55%
US
PBE
+1.60%
US
IBB
+2.27%
Market Beat·
US
INCY
+1.55%
US
PBE
+1.60%
US
IBB
+2.27%

Incyte Corp. Stock Underperforms Friday When Compared To Competitors

MarketWatch Automated·
US
INCY
+1.55%
MarketWatch Automated·
US
INCY
+1.55%

Incyte Corp. Stock Underperforms Thursday When Compared To Competitors

MarketWatch Automated·
US
INCY
+1.55%
US
PBE
+1.60%
US
LABU
+11.76%
MarketWatch Automated·
US
INCY
+1.55%
US
PBE
+1.60%
US
LABU
+11.76%

Incyte Corp. Stock Underperforms Tuesday When Compared To Competitors

MarketWatch Automated·
US
INCY
+1.55%
US
ARKG
+5.05%
US
BBH
+0.96%
MarketWatch Automated·
US
INCY
+1.55%
US
ARKG
+5.05%
US
BBH
+0.96%

Prelude Therapeutics Inc 1Q 2026: Revenue $4.58M, EPS $(0.13) — 10-Q Summary

TradingView·
US
PRLD
+5.39%
US
INCY
+1.55%
TradingView·
US
PRLD
+5.39%
US
INCY
+1.55%
© 2026 Longbridge｜Disclaimer